{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T21:15:45Z","timestamp":1784495745931,"version":"3.55.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Bone scintigraphy using technetium-99\u00a0m-labelled phosphonates is increasingly applied for imaging of cardiac transthyretin (ATTR) amyloidosis. However, there is limited data on how frequently this technique is used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>To address this issue, we added questions about the number of patients referred for nuclear medicine scanning for suspected cardiac amyloidosis and the proportion of positive results (Perugini score of 2 or 3) to the 2024 survey on myocardial perfusion imaging conducted jointly in Germany, Austria and Switzerland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of participating institutions in Austria, Germany and Switzerland was 12, 170 and 16, respectively. The number of patients scanned for cardiac amyloidosis was 1487, 4029 and 824 with a positivity-rate of 41%, 37% and 49%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The survey data reveal an increasing diagnostic effort for cardiac amyloidosis from 2021 to 2024, with a similar trend observed in all three countries. The average positivity rate in 2024 was almost 40% vs. about 33% in 2021. The results from 2021 to 2024 across all participants demonstrate improved pre-selection by the referring physicians but also increased awareness and improved training among nuclear medicine physicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07601-8","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T03:44:04Z","timestamp":1759376644000},"page":"1113-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3777-0052","authenticated-orcid":false,"given":"Oliver","family":"Lindner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bucerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Derlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Buechel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"7601_CR1","first-page":"e000029","volume":"14","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA, et al. \/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021;14:e000029.","journal-title":"Circ Cardiovasc Imaging"},{"key":"7601_CR2","unstructured":"ASNC und EANM. Deutsche Gesellschaft f\u00fcr Nuklearmedizin. Kardiale Amyloidose. Leitfaden f\u00fcr die Praxis. www.asnc.org\/wp-content\/uploads\/2024\/05\/19110-ASNC-AND-EANM-Amyloidosis-Practice-Points_LRes19-1.pdf"},{"key":"7601_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","volume":"7","author":"S Longhi","year":"2014","unstructured":"Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531\u20132.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7601_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","volume":"14","author":"TJ Poterucha","year":"2021","unstructured":"Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: A test in evolution. JACC Cardiovasc Imaging. 2021;14:1221\u201331.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7601_CR5","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00259-023-06129-z","volume":"50","author":"O Lindner","year":"2023","unstructured":"Lindner O, Sch\u00e4fer W, Rischpler C, Silber S, Burchert W. Myocardial perfusion SPECT in Germany from 2012 to 2021: insights into development and quality indicators. Eur J Nucl Med Mol Imaging. 2023;50:1621\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07601-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:46:17Z","timestamp":1769222777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07601-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7601"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07601-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7240846\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was reviewed by the Ethics Committee of the Medical Faculty Ruhr University Bochum, Ostwestfalen (Az 2025\u2009\u2212\u20091424). The statement was that neither a positive evaluation nor a consultation by an ethics committee is necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Nothing to Disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}